États-Unis - anglais - NLM (National Library of Medicine)

it3 medical llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp 3a4 inhibitors) dihydroergotamine mesylate injection, usp should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant angina. (see

États-Unis - anglais - NLM (National Library of Medicine)

impel pharmaceuticals inc. - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - trudhesa is indicated for the acute treatment of migraine with or without aura in adults. limitations of use trudhesa is not indicated for the preventive treatment of migraine. trudhesa is not indicated for the management of hemiplegic or basilar migraine. trudhesa is contraindicated in patients: - with concomitant use of strong cyp3a4 inhibitors, such as protease inhibitors (e.g., ritonavir, nelfinavir, or indinavir), macrolide antibiotics (e.g., erythromycin or clarithromycin), and antifungals (ketoconazole or itraconazole) [see warnings and precautions (5.1) and drug interactions (7.1)] - with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including prinzmetal's variant angina [see warnings and precautions (5.4)] - with uncontrolled hypertension [see warnings and precautions (5.5)] - with peripheral arterial disease - with sepsis - following vascular surge

Irlande - anglais - HPRA (Health Products Regulatory Authority)

polichem s.a. - dihydroergotamine mesilate - tablets - 20 milligram

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bromocriptine mesilate -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bromocriptine mesilate -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bromocriptine mesilate -

Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amdipharm ltd. - dihydroergotamine mesilate 2,5 mg - tablet - dihydroergotamine

Canada - anglais - Health Canada

sterimax inc - dihydroergotamine mesylate - liquid - 0.5mg - dihydroergotamine mesylate 0.5mg - sympatholytic (adrenergic blocking) agents

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dihydroergotamine 0.714 mg/ml; heparin 7142.8 iu/ml; lidocaine 10.66 mg/ml - solution for injection - 0.7 ml - active: dihydroergotamine 0.714 mg/ml heparin 7142.8 iu/ml lidocaine 10.66 mg/ml

Irlande - anglais - HPRA (Health Products Regulatory Authority)

polichem s.a. - dihydroergotamine mesilate - tablets - 20 milligram